Partnerships Are Key To Foundation Medicine's Success

Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.

Gaurav Singal Foundation Medicine
Gaurav Singal, Foundation Medicine's chief data officer, discussed the company's successful FDA product applications and CMS reimbursements. • Source: Foundation Medicine

More from Business

More from Medtech Insight